Get started
Author

Valérie Lebrun-Ly

Observed names: Lebrun-Ly, Valérie, V Lebrun-Ly, V. Lebrun-Ly, VALERIE LEBRUN-LY, Valerie Lebrun-Ly, Valérie LEBRUN-LY
Observed institutions: Université de Bordeaux, Inserm, Université de Montpellier, Institut Gustave Roussy, Hôpital Cochin, CHU Dijon Bourgogne, Centre Hospitalier Universitaire de Limoges, Institut Bergonié, Hôpital Universitaire Dupuytren, Canadian Cancer Trials Group, Institut Curie
ORCID: 0000-0002-0188-1773
Observed ORCID: 0000-0002-0188-1773
OpenAlex ID: A5041015838
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial
2022 · Thierry Conroy, Florence Castan, et al. · JAMA Oncology · 402
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
2022 · Patricia Pautier, Antoine Italiano, et al. · The Lancet Oncology · 144
PDF
Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
2024 · Patricia Pautier, Antoine Italiano, et al. · New England Journal of Medicine · 97
PDF
Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study
2020 · Marie Selvy, Bruno Pereira, et al. · Journal of Clinical Medicine · 77
PDF
Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy
2005 · Agnès Sparsa, Nicolas Lesaux, et al. · Journal of the American Academy of Dermatology · 67
Quality of Life of Patients With Cancer During the COVID-19 Pandemic
2021 · KIM-ARTHUR BAFFERT, TIFFANY DARBAS, et al. · In Vivo · 48
PDF
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma
2025 · Michel Ducreux, Romain Desgrippes, et al. · Journal of Clinical Oncology · 45
Conservative surgery vs. duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors (GIST): A retrospective review of 114 patients from the French Sarcoma Group (FSG)
2014 · F. Duffaud, P. Meeus, et al. · European Journal of Surgical Oncology · 30
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery
2021 · P. Pautier, A. Floquet, et al. · ESMO Open · 29
PDF
Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up
2007 · D Genet, C Lejeune, et al. · British Journal of Cancer · 24
PDF
Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered
2007 · Laurence Vénat-Bouvet, Franck Saint-Marcoux, et al. · Anti-Cancer Drugs · 23
Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC
2023 · Pierre Kubicek, Axel Le Cesne, et al. · BMC Cancer · 17
PDF
LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study
2021 · P. Pautier, A. Italiano, et al. · Annals of Oncology · 14
Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy
2021 · Nicolas Kerckhove, Marie Selvy, et al. · Frontiers in Pharmacology · 12
PDF
Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life
2024 · David Balayssac, Nicolas Kerckhove, et al. · Supportive Care in Cancer · 11
PDF
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study
2024 · Alexis Trecourt, Naoual Bakrin, et al. · Annals of Surgical Oncology · 10
PDF
[MRI evaluation of primary chemotherapy response in breast cancer].
2004 · Laurence Vénat-Bouvet, Michèle Desfougères, et al. · PubMed · 7
Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence
2021 · Yacine Zouhry, Abdelkader Taibi, et al. · BMC Cancer · 3
PDF
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)
2024 · Jean-Louis Legoux, Roger Faroux, et al. · Cancers · 2
PDF
ONCOGRAM: study protocol for the evaluation of therapeutic response and survival of metastatic colorectal cancer patients treated according to the guidelines of a chemosensitivity assay, the Oncogramme®
2021 · Muriel Mathonnet, Mathieu Vanderstraete, et al. · Trials · 2
PDF
Doxorubicin-Trabectedin With Trabectedin Maintenance in Leiomyosarcoma
2025 · Patricia Pautier, Antoine Italiano, et al. · Obstetrical & Gynecological Survey · 1
429P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: First results of the randomized phase II TIME-PRODIGE28 UNICANCER study according to RAS/BRAF status
2021 · V. Boige, E. Francois, et al. · Annals of Oncology · 1
PDF
444P PRODIGE 25 (FFCD 11-01)-FOLFA: A randomized phase II trial evaluating aflibercept associated with LV5FU2 regimen as first-line treatment of non-resectable metastatic colorectal cancers
2020 · J.L. Legoux, R. Faroux, et al. · Annals of Oncology · 1
ASO Visual Abstract: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study
2024 · Alexis Trecourt, Naoual Bakrin, et al. · Annals of Surgical Oncology
394P Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34-FFCD 1402-ADAGE randomized phase III trial
2021 · T. Aparicio, O. Bouche, et al. · Annals of Oncology
Works count: 39
Citation count: 1,211
H-index: 14
I10-index: 17
Year
Topic
Type